Status:
COMPLETED
The Use of ACE Inhibitors in the Early Renal Post-transplant Period
Lead Sponsor:
Montefiore Medical Center
Conditions:
Renal Transplant
Eligibility:
All Genders
21-80 years
Phase:
PHASE1
Brief Summary
Chronic allograft nephropathy (CAN) is the leading cause of longterm renal transplant loss. Angiotensin-II may play a role in the development and progression of CAN. Angiotensin converting enzyme inhi...
Detailed Description
All new renal transplant recipients with functioning allografts and serum creatinine less than 2.6 mg/dl within the first 3 month post transplant would be eligible for this study of the safety of enal...
Eligibility Criteria
Inclusion
- New adult renal transplant recipients with good renal function defined as serum creatinine less than 2.6 mg/dl,
- Normal serum potassium levels,
- No contraindication to ACE inhibitor use
Exclusion
- Renal transplant patients with persistent serum creatinine levels over 2.5 mg/dl
- Hyperkalemia with serum potassium levels over 5.5 mEQ/dl
- History of allergic reaction to ACE inhibitors or angiotensin receptor blockers
- Pregnancy
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00270153
Start Date
September 1 2004
End Date
December 1 2009
Last Update
February 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montefiore Medical Center
The Bronx, New York, United States, 10467-2490